Paper OK, title wrongBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d2732 (Published 10 May 2011) Cite this as: BMJ 2011;342:d2732
- Nicholas Moore, professor and head1
- 1Department of Pharmacology, University of Bordeaux, 33076 Bordeaux, France
The paper at the centre of the recent news article used disproportionality analysis to compare reports of pancreatitis and pancreatic or thyroid cancer to the US Food and Drug Administration associated with sitagliptine or exenatide versus four other drugs used in diabetes—rosiglitazone, nateglinide, repaglinide, and glipizide.1 2 They found …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial